Adaptive Biotechnologies Corp (NAS:ADPT)
$ 3.32 -0.14 (-4.06%) Market Cap: 489.26 Mil Enterprise Value: 296.04 Mil PE Ratio: 0 PB Ratio: 1.77 GF Score: 72/100

Adaptive Biotechnologies Corp at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 09:30PM GMT
Release Date Price: $4.65 (-1.69%)
Rachel Vatnsdal JPMorgan Chase;Co.;Analyst

&-

Perfect. Good afternoon, everyone. This is Rachel Vatnsdal with the life science tools and diagnostics team at JP Morgan. I'm joined by the Adaptive team up here on stage.

And this is going to be a 40-minute session, roughly 20, 25 minutes of presentation, followed by Q&A. If any of you in the room have questions, feel free to either submit them via the app or you can ping me directly. With that, I will pass it up to Chad.

Chad Robins
Adaptive Biotechnologies Corp - Chairman of the Board, Chief Executive Officer, Co-Founder

Awesome. Thank you, Rachel. Appreciate the opportunity to present once again at JP Morgan. I want to wish you Happy New Year and welcome everyone in the room and those of you who are also listening by webcast. For those of you who are new to the company, Adaptive's mission is to translate the genetics of the adaptive immune system to create clinical products to both detect and treat disease.

Throughout the last decade, we pioneered two exciting

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot